コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 oup (one CMV; one EBV-related posttransplant lymphoproliferative disorder).
2 There were no cases of lymphoproliferative disorder.
3 ow incidence of EBV reactivation without EBV-lymphoproliferative disorder.
4 xperience higher incidence of posttransplant lymphoproliferative disorder.
5 stleman disease (MCD) is a polyclonal B-cell lymphoproliferative disorder.
6 entric Castleman disease (MCD) as a distinct lymphoproliferative disorder.
7 ing Burkitt lymphoma (BL) and posttransplant lymphoproliferative disorder.
8 at a median of 96 days with no incidence of lymphoproliferative disorder.
9 ablation results in a fulminating and fatal lymphoproliferative disorder.
10 e rejection, sepsis, and posttransplantation lymphoproliferative disorder.
11 rious EBV diseases, including posttransplant lymphoproliferative disorder.
12 human malignancies, including posttransplant lymphoproliferative disorder.
13 ioimmunoblastic T cell lymphoma is a complex lymphoproliferative disorder.
14 the other as a result of posttransplantation lymphoproliferative disorder.
15 ere were no retransplants or post-transplant lymphoproliferative disorder.
16 without increasing the risk of infection or lymphoproliferative disorder.
17 cytomegalovirus infection or posttransplant lymphoproliferative disorder.
18 risks, such as infectious mononucleosis and lymphoproliferative disorder.
19 ble, display fully penetrant female-specific lymphoproliferative disorder.
20 g a possible explanation for female-specific lymphoproliferative disorder.
21 , a life-threatening, virally induced B-cell lymphoproliferative disorder.
22 5 x 10(9)/L B-cells and no other signs of a lymphoproliferative disorder.
23 al B-cell, and 1 CR of 3 with posttransplant lymphoproliferative disorder.
24 skin, solid malignancies, and posttransplant lymphoproliferative disorder.
25 LYG) is a rare Epstein-Barr virus-associated lymphoproliferative disorder.
26 virus that causes Kaposi's sarcoma and other lymphoproliferative disorders.
27 enia, chronic EBV infection, and EBV-related lymphoproliferative disorders.
28 nctional polarization was examined in T-cell lymphoproliferative disorders.
29 ribute to the development of KSHV-associated lymphoproliferative disorders.
30 activation can be operative in these chronic lymphoproliferative disorders.
31 acroglobulinemia, and 57 with B-cell chronic lymphoproliferative disorders.
32 of progression to late-onset posttransplant lymphoproliferative disorders.
33 ved Kaposi sarcoma (KS) and also for certain lymphoproliferative disorders.
34 introduced to reduce risk of posttransplant lymphoproliferative disorders.
35 er clinical pursuit in this and other B-cell lymphoproliferative disorders.
36 other cell types in blood from patients with lymphoproliferative disorders.
37 targeted therapy for CLL and related B-cell lymphoproliferative disorders.
38 sly undescribed role for monocytes in T-cell lymphoproliferative disorders.
39 e role of chronic antigenic stimulation in B-lymphoproliferative disorders.
40 cells predisposes toward the development of lymphoproliferative disorders.
41 rvival factor, is elevated in autoimmune and lymphoproliferative disorders.
42 a viable target for mAb treatment of B-cell lymphoproliferative disorders.
43 educed intensity transplantation in indolent lymphoproliferative disorders.
44 clinical forms of Kaposi sarcoma and several lymphoproliferative disorders.
45 mplicated in the development of KSHV-induced lymphoproliferative disorders.
46 ion with HTLV-2 has not been associated with lymphoproliferative disorders.
47 ripheral and central) and haematological and lymphoproliferative disorders.
48 esis and angiogenic factors are increased in lymphoproliferative disorders.
49 portant in the progression or maintenance of lymphoproliferative disorders.
50 t and aggressive NHL as well as other B-cell lymphoproliferative disorders.
51 t been conclusively linked to development of lymphoproliferative disorders.
52 an give rise to Kaposi's sarcoma and several lymphoproliferative disorders.
53 s and in the neoplastic cells in most B-cell lymphoproliferative disorders.
54 ologic agent of Kaposi's sarcoma and several lymphoproliferative disorders.
55 ll leukemia/lymphoma (ATLL) and a variety of lymphoproliferative disorders.
56 h HTLV-2 has not been conclusively linked to lymphoproliferative disorders.
57 virus is etiologically linked to two B cell lymphoproliferative disorders.
58 munodeficiency with Epstein-Barr virus (EBV)-lymphoproliferative disorders.
59 al differences in the pathogenesis of B-cell lymphoproliferative disorders.
60 ted with neurological, gastrointestinal, and lymphoproliferative disorders.
61 increases in cardiovascular event risk, and lymphoproliferative disorders.
62 mechanisms underlying HCV-associated B-cell lymphoproliferative disorders.
63 twork of target mRNAs associated with B-cell lymphoproliferative disorders.
64 somal locus 6q14.1, a mutational hot spot in lymphoproliferative disorders.
65 wel disease (IBD), rheumatoid arthritis, and lymphoproliferative disorders.
66 have also been found in patients with other lymphoproliferative disorders.
67 by its association with a variety of T-cell lymphoproliferative disorders.
68 targeted therapy for CLL and related B-cell lymphoproliferative disorders.
69 omplications, enteropathy, autoimmunity, and lymphoproliferative disorders.
70 is associated with an increased incidence of lymphoproliferative disorders.
73 expression in cases of human posttransplant lymphoproliferative disorder, a malignant condition asso
74 with B cell proliferation and posttransplant lymphoproliferative disorder after allogeneic bone marro
75 mia (WM) cases, and the clustering of B-cell lymphoproliferative disorders among first-degree relativ
77 CTLA-4-deficient (CTLA-4KO) mice develop a lymphoproliferative disorder and die within 4 weeks of b
78 ient in a functional Foxp3, exhibit a severe lymphoproliferative disorder and display generalized ove
79 of chronic organ rejection, post-transplant lymphoproliferative disorder and graft-versus-host disea
80 t presentations of primary cutaneous CD30(+) lymphoproliferative disorder and present recommendations
82 tive agent of most immune deficiency-related lymphoproliferative disorders and is associated with var
83 Rituximab improves outcomes for persons with lymphoproliferative disorders and is increasingly used t
84 distinction between MALT lymphoma and other lymphoproliferative disorders and led to the identificat
85 s for familial MGUS and myeloma, the risk of lymphoproliferative disorders and other malignancies amo
86 re was no association between posttransplant lymphoproliferative disorders and pretransplant MGUS.
87 n the suppression of host immunity in T-cell lymphoproliferative disorders and suggest that the targe
88 rstanding the viral associations in specific lymphoproliferative disorders and the molecular mechanis
89 levels were elevated in patients with B-cell lymphoproliferative disorders and to determine whether e
90 BL), HIV-associated lymphoma, posttransplant lymphoproliferative disorder, and nasopharyngeal carcino
91 ant pancreatic insufficiency, posttransplant lymphoproliferative disorder, and postsplenectomy sepsis
92 fic immunosuppression, including infections, lymphoproliferative disorders, and non-lymphoid malignan
99 Multicentric Castleman disease (MCD) is a lymphoproliferative disorder associated with human herpe
101 we examined 811 consecutive cases of B-cell lymphoproliferative disorders (B-LPDs), and demonstrated
102 primary cutaneous CD4(+) small/medium T-cell lymphoproliferative disorder" because of its indolent cl
103 rviving CD28-deficient scurfy mice still had lymphoproliferative disorder, but their CD4 T cells show
104 y factor in the pathogenesis of the atypical lymphoproliferative disorder Castleman's disease (CD).
105 entric Castleman disease (HIV-MCD) is a rare lymphoproliferative disorder caused by infection with hu
106 ymphomas (CTCLs) are a heterogenous group of lymphoproliferative disorders caused by clonally derived
107 ome of patients with CD30+ primary cutaneous lymphoproliferative disorders (CD30CLPD) and early mycos
109 Chronic active EBV disease (CAEBV) is a lymphoproliferative disorder characterized by markedly e
110 arge granular lymphocytic leukemia is a rare lymphoproliferative disorder characterized by the expans
111 ces an aggressive, fatal, and transplantable lymphoproliferative disorder characterized by the expans
112 ll chronic lymphocytic leukemia (B-CLL) is a lymphoproliferative disorder characterized by the surfac
113 ting immunoglobulins that occur secondary to lymphoproliferative disorders, chronic viral infections,
114 response to immunotherapy, autoimmunity, and lymphoproliferative disorders, contributing overall to p
115 noglobulin gene rearrangements in context of lymphoproliferative disorders demonstrated excellent cle
116 lymphocytic leukemia (CLL) and other B-cell lymphoproliferative disorders display familial aggregati
117 Multicentric Castleman's disease is a rare lymphoproliferative disorder driven by dysregulated prod
118 sease describes a group of poorly understood lymphoproliferative disorders driven by proinflammatory
119 eated with CsA developed posttransplantation lymphoproliferative disorder during the follow-up period
122 nting a spectrum of primary cutaneous T cell lymphoproliferative disorders expressed CD25 and TGF-bet
123 macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined c
124 macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined c
125 cific prevalence and rates of progression to lymphoproliferative disorders for light-chain and conven
127 coexpression distinguished cutaneous CD30(+) lymphoproliferative disorders from MF large-cell transfo
128 f the diffuse cystic lung diseases caused by lymphoproliferative disorders, genetic mutations, or abe
129 lications post-ITx, including posttransplant lymphoproliferative disorder, graft-versus-host disease,
130 ive with no single example of posttransplant lymphoproliferative disorder, graft-versus-host disease,
131 r, cladribine's impressive activity in other lymphoproliferative disorders has been generally underap
133 Bacteria can induce human lymphomas, whereas lymphoproliferative disorders have been described in pat
135 the development of EBV-associated lymphomas, lymphoproliferative disorders, hemophagocytic lymphohist
136 ia is a major risk factor for posttransplant lymphoproliferative disorder; however, immune correlates
137 tients with classic hydroa vacciniforme-like lymphoproliferative disorder (HVLPD) typically have high
138 ase virus (MDV), a herpesvirus that causes a lymphoproliferative disorder in chickens, encodes a numb
139 cation of typical features of CAD-associated lymphoproliferative disorder in the bone marrow was grea
141 ogren's syndrome in 22.5% of patients and to lymphoproliferative disorders in 28.7% of patients, and
143 fection that often develops into more severe lymphoproliferative disorders in immune-compromised anim
146 genesis of the interstitial lung disease and lymphoproliferative disorders in patients with CVID.
147 , a B cell lymphotrophic virus, is linked to lymphoproliferative disorders in people who have seconda
148 x 10(9)/L, and no other features of a B-cell lymphoproliferative disorder including lymphadenopathy/o
149 enic human virus, is associated with several lymphoproliferative disorders, including Burkitt lymphom
150 ought to increase the risk of malignancy and lymphoproliferative disorders, including hemophagocytic
151 which are associated with the development of lymphoproliferative disorders, including lymphomas, reac
152 EBV-infected B cells causes life-threatening lymphoproliferative disorders, including mostly germinal
153 s (EBV) infection is associated with several lymphoproliferative disorders, including posttransplant
154 miR-155 acts as an oncogenic miR in B-cell lymphoproliferative disorders, including Waldenstrom mac
155 tasizing neoplasms, polyclonal or monoclonal lymphoproliferative disorders, infections, interstitial
156 he pathogenesis of Kaposi's sarcoma (KS) and lymphoproliferative disorders, infects a variety of targ
159 , the prognosis of primary cutaneous CD30(+) lymphoproliferative disorders is excellent; however, rel
160 The role of such stromal cells in T-cell lymphoproliferative disorders is incompletely understood
161 or of interleukin-6 that is linked to B-cell lymphoproliferative disorders, is downregulated when eit
162 ge, the CD45 E613R (WEDGE) mutation led to a lymphoproliferative disorder (LPD) and a lupus-like auto
163 the wedge, the CD45 E613R mutation led to a lymphoproliferative disorder (LPD) and a lupus-like auto
164 y et al describe cases of an indolent T-cell lymphoproliferative disorder (LPD) of the gastrointestin
166 t an exhaustive search for pathogenic DNA in lymphoproliferative disorders (LPD) of the ocular adnexa
167 thrombocytopenia (ITP) secondary to chronic lymphoproliferative disorders (LPDs) is poorly responsiv
169 presents a potential treatment for the CD30+ lymphoproliferative disorder lymphomatoid papulosis (LyP
171 lobulin gene enhancer, develop a CD5+ B cell lymphoproliferative disorder mimicking human CLL and imp
172 s (miR-223), immune function (miR-155) and B-lymphoproliferative disorders (miR-155 and miR-17 approx
173 C virus (HCV) is associated with the B-cell lymphoproliferative disorders mixed cryoglobulinemia (MC
175 ed multicentric Castleman disease (MCD) is a lymphoproliferative disorder most commonly observed in H
176 lticentric Castleman disease (KSHV-MCD) is a lymphoproliferative disorder, most commonly seen in HIV-
177 s (KSHV) is causatively linked to two B cell lymphoproliferative disorders, multicentric Castleman's
178 =2), chronic rejection (n=3), posttransplant lymphoproliferative disorder (n=1), graft dysmotility or
182 an Epstein-Barr virus (EBV)-positive T-cell lymphoproliferative disorder of childhood that occurs ma
183 nular lymphocytic (LGL) leukemia is a clonal lymphoproliferative disorder of CTL associated with cyto
188 h it establishes latency, and can also cause lymphoproliferative disorders of these cells manifesting
190 stein Barr virus-related posttransplantation lymphoproliferative disorder, one of which developed aft
191 oved QALYs, without increased posttransplant lymphoproliferative disorder or cytomegalovirus disease,
192 that aberrant cell cycle control can lead to lymphoproliferative disorders or lymphoid malignancies.
194 e, proteinuria, c-peptide, viral infections, lymphoproliferative disorders or posttransplant diabetes
195 lymphomas encompass a wide spectrum of rare lymphoproliferative disorders originating in the skin, a
196 ival with lower incidence of post-transplant lymphoproliferative disorder (P = 0.09) and graft versus
197 gent for Kaposi's sarcoma (KS) and two other lymphoproliferative disorders, primary effusion lymphoma
198 tein-Barr virus (EBV)-related posttransplant lymphoproliferative disorder (PTLD) after a rituximab-ba
200 Epstein-Barr virus (EBV) posttransplantation lymphoproliferative disorder (PTLD) after UCB transplant
201 tandard in the management of post-transplant lymphoproliferative disorder (PTLD) and identified respo
202 based chemotherapy for a posttransplantation lymphoproliferative disorder (PTLD) and is disease-free
203 Patients at greatest risk of posttransplant lymphoproliferative disorder (PTLD) are those who acquir
204 new safety signals and no new posttransplant lymphoproliferative disorder (PTLD) cases after month 18
206 ssociated with development of posttransplant lymphoproliferative disorder (PTLD) following allogeneic
207 guished untreated, EBV(+)posttransplantation lymphoproliferative disorder (PTLD) from EBV(+)PTLD in r
208 /CT for the detection of posttransplantation lymphoproliferative disorder (PTLD) in a pediatric popul
209 the relationship between posttransplantation lymphoproliferative disorder (PTLD) incidence and presen
223 nded first-line treatment for posttransplant lymphoproliferative disorder (PTLD) is reduction in immu
226 pressive regimens (ISRs) with posttransplant lymphoproliferative disorder (PTLD) may be related with
227 n-Barr virus (EBV)-associated posttransplant lymphoproliferative disorder (PTLD) remains a major caus
228 atment, and outcomes of post-transplantation lymphoproliferative disorder (PTLD) that occurred at the
229 scribe a form of plasmacytic post-transplant lymphoproliferative disorder (PTLD) that occurs in pedia
230 n EBV+ B cell lymphomas from post-transplant lymphoproliferative disorder (PTLD) to discover virally
232 aised the question of whether posttransplant lymphoproliferative disorder (PTLD), a complication of i
243 ith the highest incidence was posttransplant lymphoproliferative disorder (PTLD, 1.58%), followed by
244 al Treatment of CD20-Positive Posttransplant Lymphoproliferative Disorder (PTLD-1) trial established
245 dition to a 0.4% incidence of posttransplant lymphoproliferative disorders (PTLD) and a 0.2% incidenc
246 e syndromes of EBV-associated posttransplant lymphoproliferative disorders (PTLD) and Kaposi's sarcom
249 between patients who develop posttransplant lymphoproliferative disorders (PTLD) early or late after
250 iated with increased risk for posttransplant lymphoproliferative disorders (PTLD) in liver transplant
251 We previously reported that posttransplant lymphoproliferative disorders (PTLD) occurred more frequ
254 skin cancers [NMSCs]), post-transplantation lymphoproliferative disorders (PTLD), and first and subs
267 crolimus or cyclosporine) and posttransplant lymphoproliferative disorders related to chronic immunos
269 man granzyme B promoter in mice results in a lymphoproliferative disorder resembling adult T-cell leu
272 mouse spontaneously develops a CD5(+) B cell lymphoproliferative disorder similar to human chronic ly
273 orders such as systemic lupus erythematosus; lymphoproliferative disorders such as chronic lymphocyti
274 itis C virus (HCV) is associated with B-cell lymphoproliferative disorders such as mixed cryoglobulin
275 progressive kidney failure in the setting of lymphoproliferative disorders, such as multiple myeloma,
276 BV infection (CAEBV) characterized by T cell lymphoproliferative disorders (T-LPD) of unclear etiolog
277 t frequent type of leukaemia in adults, is a lymphoproliferative disorder that is characterized by th
278 4-deficient mice develop a lethal autoimmune lymphoproliferative disorder that is strictly dependent
279 rrier function, resulting in a more severe B-lymphoproliferative disorder that persisted into adultho
281 ell lymphomas represent a group of poor-risk lymphoproliferative disorders that have only recently be
282 e in vitro findings would be of relevance to lymphoproliferative disorders that occurred in patients
284 entric Castleman disease (HIV MCD) is a rare lymphoproliferative disorder, the incidence of which app
285 nd from polyclonal HHV8-positive plasmacytic lymphoproliferative disorders to bone marrow failure and
286 EBV is also associated with a variety of lymphoproliferative disorders, typically of B cell origi
287 g and could contribute to the development of lymphoproliferative disorders via constitutive NF-kappaB
290 ttransplant malignancies, and posttransplant lymphoproliferative disorder were 3.2 (1.6-5.7), 3.2 (1.
294 s may prove to be useful in the treatment of lymphoproliferative disorders, wherein clonal expansion
295 neoplasms are a rare form of posttransplant lymphoproliferative disorder, which could be complicated
296 Hodgkin and Hodgkin lymphomas, as well as in lymphoproliferative disorders, which occur more commonly
297 hey had multiple myeloma or any other B cell lymphoproliferative disorder with end-organ damage.
298 nucleotide exchange factor Rasgrp1 develop a lymphoproliferative disorder with features of human syst
299 e in murine B cells leads to a CD5(+) B cell lymphoproliferative disorder with many of the features o
300 eview specifically discusses angiogenesis in lymphoproliferative disorders, with a special emphasis o